drugset / Trial / NCT03291158
Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV
Phase 1
Withdrawn
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Innovative Medicines Initiative · collabUniversitätsklinikum Köln · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, safety and PK Open-Label trial evaluating the plasma, epithelial lining fluid, and alveolar macrophage concentrations of intravenous Minocin® (Minocycline) for injection in healthy adult subjects.
Timeline
- Start
- 2018-04
- Primary completion
- 2018-12
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Minocycline | Small molecule | — | Intravenous |
Indications
No indication recorded.